Key result
Elevated copeptin levels show an inconsistent link to metabolic syndrome.
Why the study?
Copeptin has been associated with cardiometabolic diseases, but the association between copeptin and metabolic syndrome required systematic evaluation.
Are elevated copeptin levels associated with an increased risk or prevalence of metabolic syndrome in the adult general population?
Systematic Review (n=11,699)
Are elevated copeptin levels associated with an increased risk or prevalence of metabolic syndrome in the adult general population?
Current observational evidence regarding the association between elevated copeptin levels and metabolic syndrome is inconsistent, precluding definitive conclusions without further longitudinal studies.
Inconsistent observational data preclude copeptin use for metabolic syndrome assessment; leaves open need for longitudinal studies.
Background: Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods: We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. The risk of bias was evaluated with the Newcastle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values. Results: A total of 7 studies (5 cross-sectional, 1 case-control, and 1 cohort) were included comprising 11,699 participants. Most of them were performed in the adult general population. Two cross-sectional and one case-control studies found a positive significant association between higher levels of copeptin and MetS. While three cross-sectional and one cohort studies found no association. The case-control study had several methodological limitations, most cross-sectional studies were methodologically adequate and the cohort study had no methodological issues. Conclusions: The association between copeptin and MetS is inconsistent. However, the arginine-vasopressin system impairment contributes to metabolic disorders, expressing plasma copeptin changes. Thus, more longitudinal studies are required to corroborate the association of copeptin and MetS.
No takes yet. Share an insight, caveat, or question.
Rojas-Humpire et al. (2022) conducted a systematic review in Metabolic Syndrome (n=11,699). Elevated copeptin levels vs. Patients without elevated copeptin levels was evaluated on Risk or prevalence of having Metabolic Syndrome. Elevated copeptin levels showed an inconsistent association with metabolic syndrome across 7 studies, with 3 finding a positive significant association and 4 finding no association.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: